Natco Pharma launches Carboplatin generic: what it means for Natco Pharma stock

Published on 10/20/2026 at 04:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The US launch targets a shortage and USD 27.80 million market. Natco Pharma stock has an INR 12.79 billion rights issue through October 22, 2026.

Carboplatin launch and capital plans

Natco Pharma launched Carboplatin Injection in the United States on October 19, 2026, with estimated sales of USD 27.80 million.
NATCO reported INR 7.944 billion in consolidated revenue and INR 2.065 billion in profit after tax for the first quarter of fiscal 2027.
Natco Pharma stock had a market capitalization of INR 147.4 billion as of October 19, 2026.

Natco, INE987B01026, Illustration mit AI erstellt.

Natco Pharma launched Carboplatin Injection in the United States on October 19, 2026, through its subsidiary Natco Pharma USA LLC, with estimated US sales of USD 27.80 million for the 12 months ending June 2026. The Hindu BusinessLine reported that the generic version of Paraplatin was produced in collaboration with Teyro Labs Pvt Ltd to address a critical US shortage.

US launch brings a measurable market

Carboplatin Injection is used for advanced ovarian carcinoma, including first-line combination treatment and palliative treatment after earlier chemotherapy. The launch gives Natco an oncology product tied to a clearly quantified market rather than an undated development program.

The product announcement follows a weaker first quarter. NATCO Pharma listed consolidated revenue of INR 7.944 billion and profit after tax of INR 2.065 billion for the first quarter of fiscal 2027. Those figures frame the US launch as a product-level catalyst while the broader earnings base remains central to valuation.

What do the capital plans add?

Natco's capital program remains another material factor. The company offered 17,058,082 rights shares at INR 750 each, with the subscription window running through October 22, 2026. The offer size is INR 12.79 billion, making capital deployment and potential dilution important alongside the new US product.

Three dated steps shape the story

On September 25, 2026, Natco's board approved a rights issue of up to INR 12.79 billion; on October 12, 2026, the offer opened with 17,058,082 shares at INR 750; on October 19, 2026, the company launched Carboplatin Injection in the United States. StockFin reported the offer timetable, while CNBC TV18 covered the product launch and the June-quarter figures.

Dates investors can quantify

The rights issue subscription closes on October 22, 2026, and allotment is scheduled for October 23, 2026. The next earnings date listed for Natco is November 17, 2026, for the second quarter of 2026.

Stock context remains capital intensive

Natco Pharma stock was last quoted at INR 800.85 on the NSE on October 19, 2026 at 3:30 p.m. IST. The same market data showed a 52-week range of INR 779.00 to INR 1,226.80 and market capitalization of INR 147.4 billion, placing the price 34.65 percent below the 52-week high.